Visibuilt, a Danish biotechnology company developing mycelium-based binders for low-carbon construction, has raised €3.34 million in seed funding to accelerate the commercialization of its sustainable building materials. The round was co-led by EIFO and Unconventional Ventures, with participation from Proptechfonden and returning investor EMDFonden.
Advancing Sustainable Construction Materials
The investment will help Visibuilt move beyond laboratory pilots by validating its visiBINDER technology through larger-scale production trials and industry collaborations. The company’s mycelium-based binder is designed as a lower-carbon alternative to conventional bitumen and cement for paving and infrastructure projects.
Line Kloster Pedersen, CEO and Founder of Visibuilt, said:
“Closing this seed round is an important milestone for Visibuilt. It enables us to mature our technical platform, validate our solution at a larger scale, and take the next steps towards the market.”
Sara Sande, Managing Director, Partner and Head of Direct Thematic Venture at EIFO, added:
“Concrete and asphalt production are among the largest sources of CO₂ emissions globally. If we are to truly reduce emissions, it requires new solutions in heavy industries. Visibuilt has an approach that could become an important piece of that transition.”
Thea Messel, General Partner at Unconventional Ventures, said:
“At Unconventional Ventures, we look for companies where the impact case and the commercial case are structurally identical. Visibuilt is that company. Every tonne of visiBINDER placed in a paving application displaces a tonne of fossil binder, generates royalty revenue, and reduces the embedded carbon of the infrastructure it goes into. Line has built active industrial testing relationships with Denmark’s leading concrete paver manufacturer and Copenhagen Municipality within two years of founding – without a finished production setup and without a fully derisked product. That is an unusual execution signal for a hard-tech founder at this stage, and it is why we co-led.”
Scaling Toward Commercial Validation
The funding will support expanded testing, production setup for large-scale trials, and new technical and commercial hires. These efforts are aimed at validating the technology in real-world infrastructure projects and preparing the company for future market launch.